ClinicalTrials.gg
RecruitingNCT06316778Updated Feb 24, 2025

Pelvic Floor Muscle Training for Women with Myotonic Dystrophy

An interventional study of Pelvic floor muscle training in Myotonic Dystrophy Type 1 and Urinary Incontinence, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Myotonic Dystrophy with a site in Canada — 13 open to participants now, 16 under way, 4 of them phase 3. Myotonic Dystrophy · Canada.

Planned enrollment
21st of 25
12 · median 32
Started
2024
with 7 others
No phase
8 of 28
2 open now
Primary completion
2026-12
later than 4 of 15 live
Registered
18th of 28
by date
Lead sponsor
2 of 28
Université de Sherbrooke

Among the 28 studies in Myotonic Dystrophy with a site in Canada, this one is the 21st largest by planned enrollment of the 25 interventional ones that give a count, is one of 8 that started in 2024, is one of 8 with no phase, reaches primary completion later than 4 of the 15 other live ones, and was the 18th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

13 of the 28 studies in Myotonic Dystrophy with a site in Canada are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Myotonic Dystrophy with a site in Canada, or all of them as a file.
02

Study summary

Myotonic dystrophy type 1 (DM1) is a neuromuscular disease characterized by multisystem manifestations. DM1 can affect the urinary system through the impact of the pelvic floor muscles (PFM). Urinary incontinence can occur in this situation and is often offset with compensatory measures without restoring the PFM function (e.g. sanitary pads). PFM training have already been shown to be effective in reducing or even eliminating urinary incontinence in the general population. However, no study has been the subject of this modality in people with DM1. Having recently shown that it is possible to gain strength with DM1, a strengthening protocol targeting PFM could prove effective in treating urinary incontinence. The objectives of this study are i) to assess the feasibility and acceptability of PFM training and ii) to investigate the effects of PFM training in women with DM1 with adult phenotype. A quasi-experimental study will be conducted with 12 women having a confirmed diagnosis of DM1 with urinary incontinence. Participants will follow a 12-week PFM training program, comprising weekly sessions with an experienced physiotherapist as well as a home exercise program. Outcomes measures will be assessed at baseline and at post-treatment and will include: feasibility and acceptability variables, frequency of urinary incontinence, urogynecological symptoms and their impact on quality of life, morphometry and function of PFM, and the perceived improvement following the treatments. This study has the potential to improve the management of urinary incontinence and support the implementation of pelvic floor rehabilitation services in this population.

03

Conditions studied

  • Myotonic Dystrophy Type 1
  • Urinary Incontinence

Keywords

  • Neuromuscular disease
  • Physiotherapy
  • Exercises
  • Urinary incontinence
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed medical diagnosis of myotonic dystrophy type 1 (DM1) with adult phenotype
  • symptoms of stress, urge or mixed urinary incontinence
  • able to give a free and

Exclusion criteria

Exclusion Criteria:

  • being pregnant, have given birth by vaginal delivery in the last year or plan to become pregnant in the next six months
  • present post-void residual urine ≥ 150 ml
  • have medical conditions that may have an impact on the symptoms of urinary incontinence and the response to treatments
  • present fecal incontinence (≥ 1/week) or significant prolapse (beyond the hymen)
  • have already received physiotherapy treatments in pelvic floor rehabilitation or surgery on the perineum
  • have a defibrillator, pacemaker or bladder stimulator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Pelvic floor muscle training

    Behavioral: Pelvic floor muscle training

Interventions

  • BehavioralPelvic floor muscle training

    12 weekly sessions of 60 minutes with an experienced physiotherapist, including pelvic floor muscles (PFM) exercises with biofeedback, teaching home exercises and education.

06

What researchers measure

Primary outcomes

  1. Percentage of attended treatment sessions

    To determine feasibility, the patients' adherence to treatment sessions will be recorded (present vs absent) as well as reasons for non-attendance.

    Time frame: Through treatment completion (session 1 to 12; 12 weeks of treatment)

  2. Percentage of home exercises performed

    1. The adherence rate to home exercises for each treatment group will be assessed using a daily diary. The participants will record the frequency of the exercises completed. 2. To determine feasibility by assessing adherence to treatment sessions.

    Time frame: Through treatment completion (session 1 to 12; 12 weeks of treatment)

  3. Retention rate

    To determine feasibility by assessing the percentage of participants completing the post-treatment assessment. Reason for dropouts will be compiled.

    Time frame: Baseline to Post-treatment assessment (2-week post-treatment)

  4. Recruitment rate

    To determine feasibility by assessing the percentage of participants included versus the participants screened. The barriers and reasons for refusing to participate as well as the reasons for exclusion will be documented.

    Time frame: Baseline

  5. Intervention Acceptability Questionnaire

    The Intervention Acceptability Questionnaire will be used to assess the participants' acceptability of the interventions. This questionnaire consists of 4 items measured on a VAS scale (Minimum value: 0; Maximum Value: 10). Each item is analyzed separately, with a greater score meaning higher acceptability of the intervention. This outcome measure will contribute to identifying factors limiting the acceptability of each program.

    Time frame: At baseline and after 12 weeks of treatment

Secondary outcomes

  1. Change in the frequency of urinary incontinence episodes

    Evaluated with the 7-day bladder diary (number of leak/week).

    Time frame: Baseline to post-treatment (after the 12-week program)

  2. Change in urinary incontinence symptoms

    Evaluated with the International Consultation Incontinence Questionnaire (ICIQ-UI-SF) Ranging from 0 to 21, higher scores indicate worse outcome (more urinary incontinence symptoms and a higher impact on their quality of life).

    Time frame: Baseline to post-treatment (after the 12-week program)

  3. Change in pelvic floor disorder symptoms

    Evaluated with the Pelvic Floor Disorder Inventory (PFDI). Ranging from 0 to 300, higher scores indicate worse outcome (more pelvic floor disorder symptoms).

    Time frame: Baseline to post-treatment (after the 12-week program)

  4. Change in pelvic floor disorder symptoms related impact on quality of life

    Evaluated with the Pelvic Floor Impact Questionnaire (PFIQ-SF). Ranging from 0 to 300, higher scores indicate a worse outcome (higher impact on their quality of life).

    Time frame: Baseline to post-treatment (after the 12-week program)

  5. Change in pelvic floor muscles morphometry

    Evaluated with transperineal ultrasound.

    Time frame: Baseline to post-treatment (after the 12-week program)

  6. Change in pelvic floor muscles function

    Evaluated with dynamometry.

    Time frame: Baseline to post-treatment (after the 12-week program)

  7. Patient's satisfaction

    Evaluated with Patient satisfaction questionnaire (PSQ) ranging from "completely satisfied" to "not satisfied at all".

    Time frame: Post-treatment (after the 12-week program)

  8. Patient's global impression of change

    Evaluated with Patients' Global Impression of Improvement (PGI-I). Ranging from 1 "very much better" to 7 "very much worse" on a 7-point likert scale.

    Time frame: Post-treatment (after the 12-week program)

  9. Patient's estimated improvement

    Evaluated with Estimated percent improvement (EPI). Ranging from 0 "no amelioration" to 100 "complete amelioration".

    Time frame: Post-treatment (after the 12-week program)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

Of 26 interventional studies with no phase under Myotonic Dystrophy, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2024
First posted
Mar 18, 2024
StartActual
Mar 11, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06316778
Collaborators
Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Interdisciplinary research team on neuromuscular diseases (GRIMN), CIUSSS Saguenay-Lac-Saint-Jean
Responsible party
Mélanie Morin (Researcher and full professor, Université de Sherbrooke) — Principal investigator
First posted
Mar 18, 2024
Start date
Mar 11, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Feb 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion